



26<sup>th</sup> March 2024

To,

The Secretary  
Bombay Stock Exchange Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street Mumbai 400 001  
Scrip Code: 500674

The Secretary  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra East,  
Mumbai 400 050  
Symbol: SANOFI

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“SEBI (LODR) Regulations”)**

Dear Sir/Madam,

Please find enclosed a Press Release as regards to an exclusive distribution and promotion agreement between Sanofi India Limited (SIL) and Cipla Limited for distribution and promotion of SIL’s Central Nervous System products in India for an initial period of five (5) years on terms and conditions as agreed between the Parties, effective immediately. The said agreement was approved at the Board Meeting held today.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting of Board of Directors commenced at 6:30 p.m. and concluded at 7:20 p.m.

This is for your information and records.

Thanking you,

Yours faithfully

For **Sanofi India Limited**

---

**Radhika Shah**  
**Company Secretary & Compliance Officer**  
**Membership No: A19308**

**Encl: as above**

## Press Note

### *Sanofi & Cipla announce exclusive distribution partnership to expand reach of CNS portfolio in India*

**Mumbai, March 26, 2024.** Sanofi India Limited ("SIL") (BSE: 500674 NSE: SANOFI) and Sanofi Healthcare India Private Limited (together referred as "Sanofi India") and Cipla Limited ("Cipla") (BSE:500087; NSE: Cipla EQ) today announced an exclusive partnership for distribution and promotion of Sanofi India's Central Nervous System (CNS) product range in India. As a part of this partnership, Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium®, a leading brand in the anti-epileptic medication category.

While Sanofi India will continue to own, import, and manufacture its complete range of CNS products across plants in India and internationally, Cipla will leverage its capabilities and robust India-wide network of strong marketing and sales professionals, distributors, institutions, and market outreach programs to expand access to these treatments for patients who need them.

#### ***Mr. Rodolfo Hrosz***

Managing Director, Sanofi India Limited

*"Sanofi India's CNS products are leaders in their respective categories. These well-established brands already improve lives of many patients across urban centres in the country. Cipla's wide presence will enable us to expand the reach of this portfolio to healthcare professionals and patients across all India."*

#### ***Mr. Achin Gupta***

Chief Executive Officer – One India Business, Cipla Limited

*"Enhancing access to high quality treatments is central to our purpose of 'Caring for Life'. We are pleased to collaborate with Sanofi India to enhance accessibility to highly efficacious and quality therapeutic solutions in CNS and bring value to patients across the country. Central Nervous System is one of the most challenging areas in medicine, and we believe this partnership is a significant step forward to address unmet needs of patients."*

Sanofi India continues to focus on accelerating its strong innovation pipeline into India, across multiple therapeutic areas including Diabetes, Transplants, Rare Diseases, Consumer Healthcare and Vaccines.

#### ***Sanofi - in India for India***

As Sanofi India, we are in a great place to make a difference. Present in India for nearly seven decades, we have earned the trust of our customers and stakeholders for our commitment to promoting health. As we chase the miracles of science to improve people's lives, we continue to engage across the entire

health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Our India Charitable Access Program is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. We conduct clinical trials here so that India can have quicker access to the latest from our global pipeline. Our world-class manufacturing site in Goa produces for people in India and 60+ other countries. Recognized by the 'Top® Employers Institute' – a global authority that honours excellence in people practices – for 5 years in a row (since 2019), our local entities include Sanofi India Limited (SIL - listed entity) and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

Visit us at [www.sanofi.in](http://www.sanofi.in) and [www.sanofiindialtd.com](http://www.sanofiindialtd.com), or connect with us on [LinkedIn](#) and [Twitter](#).

### *About Sanofi*

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

### *About Cipla Limited*

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Feb'24), 2<sup>nd</sup> largest in the pharma prescription market in South Africa (IQVIA MAT Jan'24), and 4th largest by prescription in the US Gx inhalation products (IQVIA MAT Sep'23). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com), or click on Twitter, Facebook, LinkedIn.

### *Media Relations*

**Aparna Thomas** | [aparna.thomas@sanofi.com](mailto:aparna.thomas@sanofi.com)

||

**Heena Kanal** | [heena.kanal@cipla.com](mailto:heena.kanal@cipla.com)

### *Agency Partner*

**Chehak Mishra** | [chehak.mishra@adfactorspr.com](mailto:chehak.mishra@adfactorspr.com)

--- ENDS HERE ---